On going treatment(s)-Biological/Targeted therapy Posts on Medivizor
Navigation Menu

On going treatment(s)-Biological/Targeted therapy Posts on Medivizor

Evaluating the health-related quality of life in patients with multiple myeloma treated with daratumumab combined with bortezomib and dexamethasone.

Evaluating the health-related quality of life in patients with multiple myeloma treated with daratumumab combined with bortezomib and dexamethasone.

Posted by on Mar 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the health-related quality of life (HRQoL) for patients with relapsed/refractory (RR) multiple myeloma (MM) patients treated with D-Vd (daratumumab, bortezomib, and dexamethasone) compared to Vd (bortezomid and dexamethasone). The study showed that HRQoL did not decrease for 8 therapy cycles and long-term...

Read More

Does age influence the safety and effectiveness of stem cell treatment for patients with multiple myeloma?

Posted by on Jul 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined the safety and effectiveness of stem cell transplantation (SCT) in elderly patients with multiple myeloma (MM) aged 65 or older compared to younger patients. The authors concluded that SCT was equally as safe and effective for patients in both age groups. Some background Multiple myeloma is a complex type of...

Read More

Stem cell transplantation and lenalidomide improves survival of patients with multiple myeloma

Stem cell transplantation and lenalidomide improves survival of patients with multiple myeloma

Posted by on Dec 5, 2018 in Multiple Myeloma | 0 comments

In a nutshell This article investigated the safety and effectiveness of high-dose therapy with autologous stem cell transplantation (HDT-ASCT) and maintenance treatment (treatment meant to keep cancer from coming back) with lenalidomide (Revlimid) for patients with multiple myeloma. The authors concluded that this therapy is safe...

Read More

What is the benefit of adding ixazomib to lenalidomide and dexamethasone for relapsing/refractory multiple myeloma?

What is the benefit of adding ixazomib to lenalidomide and dexamethasone for relapsing/refractory multiple myeloma?

Posted by on Jul 3, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effects of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone (Dexasone) for patients with unresponsive multiple myeloma. The main finding was that patients receiving ixazomib plus lenalidomide and dexamethasone survived longer without worsening of cancer (progression-free...

Read More

Carfilzomib – once weekly or twice weekly to treat unresponsive multiple myeloma?

Carfilzomib – once weekly or twice weekly to treat unresponsive multiple myeloma?

Posted by on Jun 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...

Read More

Is rituximab/bendamustine safer and more effective than R-CHOP in patients with grade 3A follicular lymphoma?

Is rituximab/bendamustine safer and more effective than R-CHOP in patients with grade 3A follicular lymphoma?

Posted by on Apr 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of the R-B (rituximab, bendamustine) regimen versus the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in patients with grade 3A follicular lymphoma (FL3A). This study concluded that R-B is better tolerated and more effective than R-CHOP, making it a...

Read More

The effectiveness of lenalidomide to treat patients with relapsed or refractory mantle cell lymphoma

Posted by on Dec 30, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared lenalidomide (Revlimid) with the doctor’s choice of medication in patients with relapsed or refractory mantle cell lymphoma. The study concluded that lenalidomide significantly improved outcomes for patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin...

Read More

Ask the Expert: Any Updates on the Use of the New Immuno-Drugs for Maintenance in Myeloma?

Ask the Expert: Any Updates on the Use of the New Immuno-Drugs for Maintenance in Myeloma?

Posted by on Dec 8, 2017 in Multiple Myeloma | 0 comments

Video information: After receiving a successful treatment, it’s recommended that patients turn to maintenance therapy to help safeguard their quality of life and help control the residual myeloma cells from developing. The landscape for maintenance therapy continues to expand as the potential effects of new immuno-drugs emerge. Listen in as...

Read More

Myeloma Update From ASCO 2017

Myeloma Update From ASCO 2017

Posted by on Oct 7, 2017 in Multiple Myeloma | 0 comments

Video information: On location at the recent 2017 American Society of Clinical Oncology meeting (ASCO), Dr. Hearn Jay Cho of Mount Sinai Hospital discusses news out of ASCO 2017 and what it means for myeloma patients and care partners. Dr. Cho highlights news out of the meeting, including how experts are manipulating the immune system, precision...

Read More

The safety and outcomes of lenalidomide treatment for patients with relapsed or difficult to treat mantle cell lymphoma

The safety and outcomes of lenalidomide treatment for patients with relapsed or difficult to treat mantle cell lymphoma

Posted by on Sep 23, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use of lenalidomide (Revlimid) treatment for patients with relapsed mantle cell lymphoma. The authors concluded that lenalidomide is generally safe and effective for treating patients with advanced stage relapsed or difficult to treat mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is an...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor